To date, two anti-PD-1 (nivolumab and pembrolizumab) antibodies and one anti-PD-L1 antibody (atesolizumab) are registered by the FDA as drugs for the treatment of NSCLC 127, 128. The gene discussed is CD274; the disease is non-small cell lung carcinoma.